Cardiovascular vs. non-cardiovascular deaths after heart failure hospitalization in young, older, and very old patients.


Journal

ESC heart failure
ISSN: 2055-5822
Titre abrégé: ESC Heart Fail
Pays: England
ID NLM: 101669191

Informations de publication

Date de publication:
Feb 2023
Historique:
revised: 26 10 2022
received: 09 05 2022
accepted: 08 11 2022
pubmed: 28 11 2022
medline: 26 1 2023
entrez: 27 11 2022
Statut: ppublish

Résumé

The long-term outcome in patients with heart failure (HF) after hospitalization may vary substantially depending on their age and left ventricular ejection fraction (LVEF). We aimed to assess the relative rates of cardiovascular death (CVD) and non-CVD based on the age and how the rates differ under the updated LVEF classification system. Consecutively registered hospitalized patients with HF (N = 3558; 39.7% women with a mean age of 73.9 ± 13.3 years) were followed for a median of 2 (interquartile range, 0.8-3.1) years. The CVDs and non-CVDs were evaluated based on age [young (<65 years), older (65-84 years), and very old (≥85 years)] and LVEF classification [HF with preserved EF (HFpEF; LVEF ≥50%) and non-HFpEF (LVEF <50%)]. The adverse clinical events were adjudicated independently by a central committee. Overall, 1505 (42.3%) had HFpEF [young: n = 182 (12.1%), older: n = 894 (59.4%), very old: n = 429 (28.5%)], and 2053 (57.7%) had non-HFpEF [young: n = 575 (28.0%), older: n = 1159 (56.5%), very old: n = 319 (15.5%)]. During the follow-up, the crude incidence of all-cause death was higher in non-HFpEF than in HFpEF across all age groups (non-HFpEF vs. HFpEF, young: 10.4% vs. 5.5%, log-rank P = 0.10; older: 26.6% vs. 20.9%, log-rank P = 0.002; very old: 36.7% vs. 31.7%, log-rank P = 0.043). CVDs accounted for more than half of all deaths in non-HFpEF (young 65.0%, older 64.2%, and very old 55.6%), whereas the proportion of CVDs remained less than half in HFpEF (young 50.0%, older 41.2%, very old 38.2%). HF readmission was associated with subsequent all-cause death in non-HFpEF [hazard ratio (HR): 1.72, 95% confidence interval (CI): 1.41-2.09, P < 0.001], but not in HFpEF (HR: 1.12, 95% CI: 0.87-1.43, P = 0.39). The probability of a non-CVD increases in both LVEF categories with advancing age, but that it is greater in the HFpEF category. The findings indicate that mitigating CV-related outcomes alone may be insufficient for treating HF in older population, particularly in the HFpEF category.

Identifiants

pubmed: 36436825
doi: 10.1002/ehf2.14245
pmc: PMC9871708
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

673-684

Subventions

Organisme : Grant-in-Aid for Young Scientists (Japan Society for the Promotion of Science KAKENHI)
ID : 18K15860
Organisme : Health Labour Sciences Research Grant
ID : 14528506
Organisme : Sakakibara Clinical Research Grant for Promotion of Sciences
ID : 2012-2020
Organisme : Japan Agency for Medical Research and Development
ID : 201439013C
Organisme : Grant-in-Aid for Scientific Research
ID : 23591062
Organisme : Grant-in-Aid for Scientific Research
ID : 26461088
Organisme : Grant-in-Aid for Scientific Research
ID : 21K08064
Organisme : Grant-in-Aid for Scientific Research
ID : 17K09526
Organisme : Grant-in-Aid for Scientific Research
ID : 16KK0186
Organisme : Grant-in-Aid for Scientific Research
ID : 16H05215

Informations de copyright

© 2022 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.

Références

Int J Cardiol. 2017 May 15;235:162-168
pubmed: 28259550
J Am Coll Cardiol. 2017 Feb 7;69(5):556-569
pubmed: 28153111
Circulation. 2014 May 27;129(21):2094-9
pubmed: 24633881
J Card Fail. 2014 Mar;20(3):174-80
pubmed: 24361802
J Am Coll Cardiol. 2019 Aug 6;74(5):601-612
pubmed: 31370950
J Card Fail. 2021 Mar 1;:
pubmed: 33663906
Am J Cardiol. 2012 Apr 1;109(7):941-6
pubmed: 22236463
Eur J Heart Fail. 2015 Jan;17(1):109-18
pubmed: 25431336
Am J Clin Nutr. 2005 Oct;82(4):777-83
pubmed: 16210706
Circulation. 2003 Jun 17;107(23 Suppl 1):I4-8
pubmed: 12814979
JACC Heart Fail. 2020 Dec;8(12):999-1008
pubmed: 33189635
Eur Heart J. 2022 Jun 14;43(23):2224-2234
pubmed: 35393622
J Am Coll Cardiol. 2022 Apr 26;79(16):1623-1635
pubmed: 35450580
J Am Heart Assoc. 2018 Sep 18;7(18):e008687
pubmed: 30371201
Circ Heart Fail. 2014 Jul;7(4):590-5
pubmed: 24874200
Lancet Glob Health. 2018 Sep;6(9):e1008-e1018
pubmed: 30103979
J Am Coll Cardiol. 2021 Jun 29;77(25):3217-3225
pubmed: 34167646
JAMA Netw Open. 2020 May 1;3(5):e204296
pubmed: 32379331
N Engl J Med. 2019 Oct 24;381(17):1609-1620
pubmed: 31475794
Eur J Heart Fail. 2021 Apr;23(4):617-628
pubmed: 33615642
Eur J Heart Fail. 2013 Jun;15(6):604-13
pubmed: 23610137
Circulation. 1993 Jul;88(1):107-15
pubmed: 8319323
J Am Coll Cardiol. 2018 May 1;71(17):1921-1936
pubmed: 29699619
Clin Res Cardiol. 2021 Aug;110(8):1249-1258
pubmed: 33399955
J Am Coll Cardiol. 2021 Feb 16;77(6):772-810
pubmed: 33446410
J Am Heart Assoc. 2020 May 18;9(10):e014949
pubmed: 32378443
N Engl J Med. 2021 Oct 14;385(16):1451-1461
pubmed: 34449189
Eur Heart J. 2021 Sep 21;42(36):3599-3726
pubmed: 34447992
ESC Heart Fail. 2023 Feb;10(1):673-684
pubmed: 36436825
Circ J. 2009 Feb;73(2):305-9
pubmed: 19096193
Circulation. 2015 Jul 28;132(4):302-61
pubmed: 25547519
N Engl J Med. 2021 Jul 15;385(3):203-216
pubmed: 33999544
Am J Kidney Dis. 2009 Jun;53(6):982-92
pubmed: 19339088
JACC Heart Fail. 2019 Aug;7(8):664-675
pubmed: 31302049
Circulation. 2021 Feb 23;143(8):e254-e743
pubmed: 33501848
Lancet. 2018 Feb 10;391(10120):572-580
pubmed: 29174292
J Card Fail. 2022 May;28(5):863-865
pubmed: 35000864
Lancet. 2020 Oct 17;396(10258):1204-1222
pubmed: 33069326
Circulation. 2018 Jul 3;138(1):80-98
pubmed: 29967232

Auteurs

Ryo Nakamaru (R)

Department of Cardiology, Keio University School of Medicine, Tokyo, Japan.
Department of Healthcare Quality Assessment, The University of Tokyo, Tokyo, Japan.

Yasuyuki Shiraishi (Y)

Department of Cardiology, Keio University School of Medicine, Tokyo, Japan.

Alexander T Sandhu (AT)

Division of Cardiology, Department of Medicine, Stanford University, Stanford, CA, USA.

Paul A Heidenreich (PA)

Division of Cardiology, Department of Medicine, Stanford University, Stanford, CA, USA.

Satoshi Shoji (S)

Department of Cardiology, Keio University School of Medicine, Tokyo, Japan.

Takashi Kohno (T)

Department of Cardiovascular Medicine, Kyorin University Faculty of Medicine, Tokyo, Japan.

Makoto Takei (M)

Department of Cardiology, Saiseikai Central Hospital, Tokyo, Japan.

Yuji Nagatomo (Y)

Department of Cardiology, National Defense Medical College, Tokorozawa, Japan.

Shintaro Nakano (S)

Department of Cardiology, Saitama Medical University, International Medical Center, Saitama, Japan.

Shun Kohsaka (S)

Department of Cardiology, Keio University School of Medicine, Tokyo, Japan.

Tsutomu Yoshikawa (T)

Department of Cardiology, Sakakibara Heart Institute, Tokyo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH